Brugada syndrome (BrS) is an arrhythmogenic disease associated with an increased risk of ventricular fibrillation (VF) and sudden cardiac death (SCD). To date, the standard therapy for the prevention of SCD in BrS is the use of an implantable cardioverter-defibrillator (ICD) especially in patients who have experienced a prior cardiac arrest or syncopal events secondary to VF. However, ICDs do not prevent the occurrence of VF but react to defibrillate the VF episode, thereby preventing SCD. Often patients with recurrent VF have to be maintained on antiarrhythmic drugs that are effective but have remarkable adverse effects. An alternative therapy for BrS with recurrent VF is catheter ablation which emerged as an effective therapy in eliminating VF-triggering premature ventricular complexes in limited case series; however, there has been a remarkable progress in effectiveness of catheter ablation since epicardial substrate ablation was first applied in 2011 and such approach is now widely applicable.
INTRODUCTION
Brugada syndrome (BrS) is characterized by ST-segment elevation in the right precordial leads and associated with life-threatening arrhythmia, mainly ventricular fibrillation (VF) that leads to sudden cardiac death (SCD). 1) Since BrS was described in 1992, 1) a tremendous number of BrS cases have been reported its incidence, up to 1-5/10,000 worldwide. 2)3) To date, the standard therapy for the prevention of SCD in BrS is the use of an implantable cardioverter-defibrillator (ICD) especially in patients who have experienced a prior cardiac arrest or syncopal events secondary to VF. 4) However, ICDs do not prevent the occurrence of VF but react to defibrillate the VF episode, thereby preventing sudden death. Often patients with recurrent VF have to be maintained on antiarrhythmic drugs that have modest effectiveness and adverse effects. Many patients have to endure recurrent ventricular tachycardia (VT)/VF episodes with associated presyncope/syncope and ICD shocks that may be painful and distressing and may cause progressive heart failure and post-traumatic stress disorder. Quinidine, an antiarrhythmic drug with blocking activity in the Ito and IKr currents, has been effective in preventing VF recurrence. 5) However, quinidine has undesirable side effects (thrombocytopenia, intolerable diarrhea, esophagitis, allergic reaction, aggravation of sinus node dysfunction, and the potential for QT prolongation and torsade de pointes) and its availability is limited especially in regions where BrS is endemic. 6) An alternative adjuvant therapy for BrS with recurrent VF was first described by Haïssaguerre et al. 7) Eight years later, there was a paradigm shift in treatment of BrS when Nademanee et al. 8) reported high efficacy of epicardial ablation to reduce VF burden. In this review, we will review the recent updates in catheter ablation for BrS.
ENDOCARDIAL APPROACH FOR BRUGADA SYNDROME
In BrS, VF-triggering premature ventricular complexes (PVCs) are almost identical, 9) site specific, 10) and predominantly originate from the right ventricular outflow tract (RVOT), which is the region hypothesized to provide slow discontinuous conduction and maximal refractoriness. 8)11)12) Kakishita et al. 9) demonstrated that many spontaneous episodes of VF in patients with BrS were preceded by frequent PVCs. They also found that preceding and initiating PVCs of a single and different VF episodes in the same patient showed the same pattern of QRS morphology and moreover, the QRS patterns of PVCs in 2 different patients were very similar to each other. 9) 
Characteristics of ventricular fibrillation-triggering premature ventricular complexes
Haïssaguerre et al. 7) first reported the electrophysiological properties and effects of catheter ablation in 3 symptomatic patients with BrS, with 1 patient exhibiting a familial SCN5A deletion mutation (2850delT). Monofocal PVCs originating from the RVOT were observed in all patients, with monofocal PVCs with left bundle-branch block (LBBB) and superior axis in 1 patient. RVOT triggers were eliminated by radiofrequency catheter ablation (RFCA) at the earliest site (25 and 40 ms before QRS onset), and VF inducibility was modified after ablation in 2 patients. In the third patient, RF energy application could ablate the PVCs originating from the anterior RV Purkinje network, thus rendered the VF non-inducible. Subsequently, other anecdotal cases were published on successful ablation of triggering ectopy within the RVOT sites in patients with this condition. 13)14) Recently we reported the largest cohort of endocardial VF ablation in BrS with the longest follow-up period. 15) In that cohort of 21 VF ablation cases, VF-triggering ectopic beat, documented in 12-lead electrocardiogram (ECG), exhibited LBBB configuration with inferior axis in 18 patients ( Figure 1A ) and superior axis in 3 patients ( Figure 1B) . The precordial QRS transition was seen in lead V3 in 4 patients, in V4 in 8 patients, and in V5 in 7 patients. The mean coupling interval of the clinical PVC was 415±57 ms.
Ventricular fibrillation-trigger ablation in Brugada syndrome
Like any trigger ablation, ablation is performed by targeting a consistent triggering PVC inducing VT/VF, localized by mapping the earliest electrogram (EGM) relative to the onset of the ectopic QRS complex before the VF during a provocation test or by reviewing the morphology of the PVC in the rhythm strip of a spontaneous VF episode. Many case series showed that VF-triggering PVCs were spontaneously observed and successfully ablated in the RVOT in 4 cases and at the right Purkinje arborization in 1 case. 7)11)12) Similarly, we found VFtriggering PVCs originated from the RVOT in 85% of the cases and from the RV itself in the rest of the cases; namely RV free wall (RVF) in 2 cases (among them only 1 case had Purkinje origin) and RV inflow tract in 1 case ( Figure 1C) . 15) 291 https://e-kcj.org https://doi.org/10.4070/kcj.2019.0344 A major limitation to trigger ablation approach is the rare occurrence of PVCs in BrS patients. 16) Therefore, all efforts should be done to identify culprit PVCs. To maximize the chance of finding VF trigger, we should attempt to obtain a 12-lead ECG during the arrhythmia episodes. Noninvasive body surface mapping, such as electrocardiographic imaging, can be used from pre-ablation and during ablation to localize PVC origin. Perfect ECG documentation can be done by obtaining 12-lead ECG during or within few days of VF or electric storm because VF-triggers appear in a narrow-time window; therefore, it is important to ablate the "culprit" PVCs that initiate VF before the index PVCs subside. 14)17) Sodium channel blockers such as pilsicainide is useful in inducing VF-triggering PVCs. A caveat to this approach is the induction of non-culprit PVC; therefore, it is extremely important to make sure that pilsicainide-induced PVC is the same as the culprit one.
Figure 1D
shows VF-triggering PVC frequently observed immediately after electrical storm of a young male who underwent emergency VF-trigger ablation. After culprit PVC elimination, VF became non-inducible after electrophysiology study (EPS) with triple RV extra-stimuli. After ablation, pilsicainide infusion could induce a PVC of RVOT origin; however, the induced PVC was different from VF-triggering PVC and was not ablated. That patient has been event free for 8 year-follow-up.
Endocardial substrate ablation in Brugada syndrome
There is no data on endocardial arrhythmogenic substrate of BrS. Shah et al. 18) first reported endocardial substrate modification in BrS. Due to the absence of clinical ectopies during EPS, endocardial ablation was performed focally on the septal and the anterolateral RVOT under the guidance of pace mapping. Initial ablation of these foci triggered flurry of non-292 https://e-kcj.org https://doi.org/10.4070/kcj.2019.0344 I   II   III   I  II  III   aVR sustained episodes of VF. Later, ectopies disappeared and ablation was reinforced in a wider area surrounding both foci (total ablation time-56 minutes). This led to the disappearance of Brugada pattern in leads V1-V2, and the ECG normalized. The ECG remained normal during the subsequent hospital stay and at every follow-up visit thereafter. The patient has not experienced any arrhythmia and the ECG has no evidence of Brugada pattern 6.5 years after ablation. 18) Using noncontact mapping, Sunsaneewitayakul et al. 19) suggested that the late depolarization zone on RVOT may serve as potential VF substrate in BrS patients who have frequent VF episodes and VF storms. RFCA on late depolarization zone modified ECG, suppressed VF storm, and reduced VF recurrence in BrS patients with VF storms. Hayashi et al. 20) could record fractionated and delayed potentials by contact bipolar mapping of the endocardium in a BrS patient. Most of those potentials were observed within low-voltage areas in various RVOT regions.
Brugada ablation
With careful endocardial mapping, we also found that endocardial fractionated EGMs were present in the most malignant Brugada phenotype i.e., in patients with extremely frequent VF episodes who had evidence of subtle conduction delay represented by QRS notching in lead V1. Although ablating RVOT-fractionated EGMs normalized the ST-segment elevation in 3 patients (Figure 2) , VF recurrence was still observed. We found that presence of QRS notch in lead V1 was invariably associated with VF recurrence despite accurate documentation of VFtriggering PVCs and extensive endocardial substrate modification, hence epicardial ablation is ultimately needed. 15) EPICARDIAL APPROACH An animal model of BrS showed that the RVOT was the main substrate site, especially at the epicardium. 21) A clear clinical evidence on the importance of epicardial substrate came from a study conducted by Nademanee et al. 8) who reported 9 BrS patients with frequent ICD discharges. All 9 patients had abnormal EGMs characterized by low voltage, and fractionated late potentials clustering at the anterior aspect of the RVOT epicardium. 8) Ablation at these sites rendered VT/VF non inducible and normalization of the Brugada ECG pattern in the majority of patients with no recurrent VT/VF in all patients off medication except 1 patient on amiodarone. 8) Moreover, an extended work by Nademanee et al. 11) showed a significant increase in collagen content in all VF victims diagnosed with BrS over and above the normal collagen content seen in age-and sex-matched controls. In the same study, biopsies taken from 6 patients with BrS during open heart ablation from RVOT epicardial sites, which harbored abnormal fragmented and delayed conduction, confirmed similar findings of fibrosis. After open heart ablation at these fibrosis sites, ECG pattern was normalized, and patients no longer had recurrent VF.
One might argue that these subtle changes and abnormal fractionated EGMs may reflect an underlying RV cardiomyopathy such as arrhythmogenic right ventricular cardiomyopathy; however, all in vivo cases had normal cardiac magnetic resonance imaging and computed tomography as well as a normal appearing heart on direct visualization during thoracotomy. into myocardium while fractionated EGM-free areas revealed neither abnormal potential nor myocardial fibrosis. Cryoablation at the abnormal EGM sites prevented VF recurrence during further 7-year follow-up, with normalization of ST elevation in precordial leads.
Epicardial substrate characteristics
Definition of abnormal epicardial substrate is still arbitrary. The most common definitions for the Brugada substrate were low voltage areas <1.5 mV, late potentials, and fragmented potentials. Nademanee et al. 8 I  II  III  V  HBE  RVS  RVF  RVF  RVF  RVF  RVF  RVF  RVF  RVF  ABL  ABL BrS. Baseline voltage map showed low voltage areas at the anterior and lateral aspects and RV and RVOT (left). After pilsicainide infusion, the low voltage areas extended to involve almost the entire anterior and lateral aspects of RV and RVOT (right). Demonstration of epicardial activation using ripple map also showed more delayed activation after using Pilsicainide infusion compared to the baseline epicardial activation (Supplementary Video 1) .
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Epicardial ablation endpoint
VT/VF non-inducibility or normalization of the Brugada ECG pattern during the ablation procedure was the initial epicardial ablation endpoint. 8) However, with more understanding of epicardial substrate and longer follow up data, it became clear that the ideal end point is to eliminate all substrate areas with low voltage fractionated signals/late potentials that can be detected by sodium channel blockade. An example is Supplementary Video 2 where baseline voltage map showed low voltage areas at the anterior and lateral aspects and RV and RVOT (left). After ablation, the low voltage areas extended to involve almost the entire anterior and lateral aspects of RV and RVOT (right) with ripple map showing only remnant late epicardial activation after ablation. Nowadays ablation is performed with irrigation catheter and preferably with contact force-based catheters that enable good epicardial contact and direct the catheter vector toward the epicardium with careful monitoring of the local EGM which can be delayed, diminished or eliminated. However, achieving "complete" substrate elimination can still be challenging.
A caveat to this approach is presence of early repolarization syndrome combined with Brugada ECG. Such patients may harbor additional VF risk even if RV/RVOT substrate elimination/ modification is achieved with guide of sodium channel blockers. An example is exhibited in Figure 5 for a young male who presented with electrical storm. Baseline ECG showed J-wave in leads V3-V6 and after very low dose pilsicainide infusion, coved type ECG pattern was observed resulting in global type early repolarization (left). Despite extensive epicardial ablation at the RV/RVOT with sodium channel blockade guide, Brugada EG pattern could be eliminated even after higher dose pilsicainide; however, lateral chest lead J-wave could not be eliminated. Such patients may remain at high risk of developing VF after ablation.
With the evidence we have so far, we think that combined approach of VF-trigger elimination if trigger ECG is well documented and non-inducibility, ECG normalization and most importantly sodium channel blockade-guided substrate elimination should all be confirmed if possible. 
CONCLUSION
SUPPLEMENTARY MATERIALS Supplementary Video 1
Demonstration of epicardial activation using ripple map of epicardial substrate of a 22-yearold male with BrS. Baseline voltage map showed low voltage areas at the anterior and lateral aspects of the RV and RVOT (left). After pilsicainide infusion, the low voltage areas extended to involve almost the entire anterior and lateral aspects of RV and RVOT (right). Demonstration of epicardial activation using ripple map also showed more delayed activation after using Pilsicainide infusion compared to the baseline epicardial activation also showed more delayed activation after using Pilsicainide infusion compared to the baseline epicardial activation.
Click here to view
Supplementary Video 2
A baseline voltage map showed low voltage areas at the anterior and lateral aspects of the epicardial RV and RVOT in a 22-year-old male with BrS (left). After ablation, the low voltage areas extended to involve almost the entire anterior and lateral aspects of RV and RVOT (right) with ripple map showing only remnant late epicardial activation after ablation.
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Pilsicainide mg Baseline Pilsicainide mg second second Figure 5 . A 12-lead ECG of a young male who presented with electrical storm. Baseline ECG showed J-wave in leads V3-V6 and after very low dose (5 mg) Pilsicainide infusion, coved type ECG pattern was observed resulting in global type early repolarization (left). Despite extensive epicardial ablation at the RV/RV outflow tract with sodium channel blockade guide, Brugada ECG pattern could be eliminated even after higher dose Pilsicainide however, lateral chest lead J-wave could not be eliminated (right). Such patients may remain at high-risk of developing VF after ablation. ECG = electrocardiogram; RFCA = radiofrequency catheter ablation; RV = right ventricular; VF = ventricular fibrillation.
